期刊
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
卷 16, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13018-021-02232-9
关键词
Total knee arthroplasty; Rheumatoid arthritis; Disease-modifying anti-rheumatic drugs; Glucocorticoids; Clinical outcome; Complication
类别
资金
- National Nature Science Foundation in China [81871740]
The study found that perioperative treatment with glucocorticoids and DMARDs can improve clinical outcomes for RA patients undergoing TKA, leading to better function, larger range of motion, and reduced postoperative pain in the long term.
Background Previous evidence suggested that perioperative anti-rheumatic therapy for patients receiving total knee arthroplasty (TKA) helped improve postoperative rehabilitation for rheumatoid arthritis (RA), yet long-term effects and outcomes of perioperative drug therapy in TKA presently remain unclear. This study investigated whether perioperative treatment with glucocorticoids (GC) and disease-modifying anti-rheumatic drugs (DMARDs) can improve clinical outcomes for patients with RA undergoing TKA. Methods Patients between January 2000 and December 2011 were allocated into three groups based on perioperative drug therapy: A, control group (no GC or DMARDs), B, DMARD group (DMARDs given without GC), and C, co-therapy group (DMARDs plus GC). The patients were followed up for average 11.4 years. Baseline characteristics, pre- and post-operative Hospital for Special Surgery score (HSS), laboratory parameters, and complications were recorded by follow-up. Results Fifty-six RA patients undergoing 91 TKAs were included in this study. Patients who received perioperative GC with DMARDs (group C) achieved larger/increased range of motion (ROM) (C:122.17 vs A:108.31 vs B:108.07, p = 0.001, partial eta squared (eta(2) p) = 0.18) at 1 year, better HSS score (C, 83.01 vs A, 79.23 vs B, 77.35, p = 0.049, eta(2) p = 0.067), pain relief (C, 1.09 vs A, 1.17 vs B, 1.75, p = 0.02, eta(2) p = 0.094), and ROM (C, 130.81 vs A, 112.82 vs B, 113.58, p = 0.001, eta(2)p = 0.142) at latest follow-up comparing with the other treatment groups. No differences were noted in laboratory tests, blood loss, volume of transfusion, or complications among groups. Conclusions Compared with the other perioperative anti-rheumatic treatments, the combination of GC and DMARDs results in improved HSS score, better function, larger range of motion, and reduced postoperative pain for TKA patients with RA in the long term. Further investigation is warranted to look for a better understanding of more specific medication effects and strike a good balance between the benefits and complications for long-term pharmacotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据